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Direct comparison of the primary structure of neutral endopeptidase (NEP, EC 3.4.24.11) with that of therrnolysin, a 
bacterial metalloendopeptidase with a similar specificity, has revealed very few similarities between the two sequences, 
except for two conserved short segments. In thermolysin, these segments contain several of the residues involved in cataly- 
sis, including two zinc coordinating histidines (His-142 and His-146) and a third histidine (His-231) involved in stabilizing 
the transition state through hydrogen bonding. The role of the corresponding histidines in NEP (His-583, His-587 and 
His-637) was explored by site-directed mutagenesis of NEP cDNA and expression of the mutated cDNA in COS-I cells. 
Substitution of either His-583 or His-587 of NEP for Phe completely abolished the activity and Zn-directed inhibitor 
recognition of the recombinant enzyme, suggesting that these residues play a role similar to His-142 and His-146 of ther- 
molysin as zinc ligands. In contrast, substitution of His-637 for a phenylalanine residue was without effect on enzyme 
activity. 
Endopeptidase 24.11; Histidine; Catalytic site; Site-directed mutagenesis 
1. INTRODUCTION 
Neutral endopeptidase (NEP, EC 3.4.24.1 I) is a 
transmembrane zinc-metalloendopeptidase found 
in the central nervous system and in many 
peripheral tissues [I 1. The role of NEP is not yet 
fully established. However its preference for small 
peptides rather than proteins and its presence at 
the cell surface suggest a possible role in the inac- 
tivation of biologically active peptides [2]. There is 
evidence in favor of a role for NEP in the degrada- 
tion of neuropeptides in the central nervous system 
[3,4]. Furthermore, inhibitors of NEP such as 
thiorphan and retrothiorphan partially protect the 
degradation of endogenous enkephalins and in- 
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duce naloxone-reversible analgesic responses [5,6]. 
NEP shares several structural features with ther- 
molysin, a bacterial metalloendopeptidase. Both 
enzymes are zinc-metalloendopeptidase and are in- 
hibited by phosphoramidon [7,8]. Their Sf subsite 
accepts exclusively hydrophobic amino acid 
residues [9], while a proline in the Pi position 
decreases the interaction with both enzymes [IO]. 
Furthermore an essential His residue present in the 
thermolysin active site was also found in NEP 
[ 11,121. Finally, comparison of the primary struc- 
ture of both enzymes has shown that many of the 
amino acids involved in catalysis and binding of 
the zinc atom in thermolysin are found in two pro- 
tein segments that have been conserved in NEP 
[ 13,141. We have recently used in vitro mutagenesis 
to test the involvement of these residues. Changing 
Glu-584 of NEP for either Val or Asp completely 
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abolished the activity of the recombinant mutant 
enzyme thereby supporting the hypothesis that this 
Glu residue is important for NEP activity [15]. 
We have now studied the role of three other 
amino acids of NEP: His-583, His-587 and His-637 
corresponding to His-142, His-146 and His-231 of 
thermolysin, respectively (see fig.1). In ther- 
molysin, the two former histidines are ligands of 
the zinc atom while the latter appears to be in- 
volved in the stabilization of the transition state 
[16]. Our results suggest hat His-583 and His-587 
are most probably two of the three ligands of the 
zinc atom in NEP. However, substituting His-637 
for Phe did not change the activity of NEP nor its 
affinity for inhibitors, indicating that His-637 is 
not directly involved in enzyme activity. 
2.4. Purr2ca:ion of NEP and enzyme assays 
NEP was purified from COS-1 cells solubilized in TBS con- 
taining 1% N-octyl-fi-D-ghtcopyranoside (octylghtcoside) [21]. 
Immunoprecipitation of the enzyme was performed with 2B12 
Mab as described elsewhere [22] and the amount of NEP was 
determined by a dot-blot assay [IS]. Enzyme assays were per- 
formed with purified NEP in 0.05 M Tris-HCl, pH 7.4, at 25°C 
using [tyrosyl-3,5-3H]Leu-enkephalin (25 nM; 34 Ci/nmol, 
Amersham) as a substrate. Separation of metabolites from the 
substrate was performed by chromatography on Cts Sep-Pak 
cartridges (Waters) as described elsewhere [22]. For Km deter- 
minations, the concentration of the substrate was varied by the 
isotopic dilution method and the values were calculated from 
Eadie-Hofstee plots. 
2.5. Diethylpyrocarbonate modification of NEP 
Purified NEP was incubated in 0.05 M Tris-HCl, pH 7.4, for 
45 min at 22°C in the presence or absence of 2 mM 
diethylpyrocarbonate (DEPC) [ 111. In some experiments, 
2 mM Phe-Leu was added before DEPC. Treatment was stop- 
ped by passage through a G-25 Sephadex column. 
2. MATERIALS AND METHODS 3. RESULTS 
2.1. Materials 
Leu-enkephalin was from Institut Armand-Frappier (Lava& 
QuC.) and diethylpyrocarbonate from Sigma. The tritiated NEP 
inhibitor [“H]-N-[(2RS)-3-hydroxyaminocarbonyl-2-benzyl- 
1-oxopropyllglycine ([3H]HACBO-Gly, 30 Ci/mmol) [17] was 
synthesized in the laboratory of one of us (B.P.R.) and tritiated 
at the Commissariat a I’Energie Atomique (CEA, Sadlay, 
France). All the other radiochemicals were from Amersham. 
2.2. Site-directed mutagenesis of NEP cDNA and expression in 
COS-I cells 
Mutagenesis of NEP was performed by oligonucleotide- 
directed mutagenesis according to Taylor et al. [18] on a Ml3 
subclone containing the proper fragment of NEP cDNA. Mu- 
tant cDNAs were screened by sequencing [19] and a fragment 
containing the mutated region was isolated from the replicating 
form of the Ml3 recombinant phage and substituted in 
pSVENK19, an expression vector using the SV40 early pro- 
motor to express NEP in COS-1 cells [15]. 
2.3. Binding of ‘251-2Bi2 monoclonal antibody and 
I’T~~HAcBO-GI~ t0 cos-1 cells 
COS-1 cell suspensions were prepared in Tris-buffered saline 
(TBS) containing 4 mM EGTA. For both lZ51-2B12 Mab and 
[3H]HACBO-Gly binding was assayed on 4 x lo5 cells [15]. 
Cells were separated from unbound ligands by centrifugation in 
an Eppendorf centrifuge and the pellets washed twice with cold 
TBS. Radioactivity due to “‘1 was determined directly on the 
cell pellets with a gamma counter whereas ‘H radioactivity was 
measured by liquid scintillation counting after dissolving the 
cells in Protosol (New-England Nuclear). The binding of 
‘251-2B12 monoclonal antibody (Mab) was used to monitor the 
presence of NEP at the cell surface. This Mab recognizes a con- 
formational epitope in the ectodomain of NEP (Aubry, 
LeGrimellec and Crine, unpublished). HACBO-Gly is a high- 
affinity non-hydrolysable NEP substrate-derived inhibitor [20]. 
The pSVENK19 plasmid contains DNA se- 
quences coding for rabbit kidney NEP inserted 
downstream of the SV40 early promotor. This vec- 
tor has already been used to induce the expression 
of NEP after transfection in COS-1 cells. The 
recombinant NEP solubilized from COS-1 cell ex- 
tracts is indistinguishable from NEP obtained 
from kidney brush borders according to several 
structural and catalytic criteria [15]. These obser- 
vations allowed us to use the COS-1 cell expression 
system to test the involvement of histidines 583, 
587, and 637 of NEP in catalysis by site-directed 
mutagenesis. In each instance, the histidine residue 
was changed for a phenylalanine residue. Expres- 
sion vectors pSVENKl9-3, pSVENKl9-6 and 
pSVENK19-7, harboring mutations for His-583, 
His-587 and His-637, respectively, were thus ob- 
tained and used to transfect COS-1 cells. Part of 
the transfected cell culture was used to monitor the 
presence of enzyme at the cell surface by measur- 
ing the binding of 1251-2B12 Mab to cell 
monolayers and the rest of the cell culture was 
lysed in the presence of octylglucoside. The recom- 
binant enzyme present in the cell extract was im- 
munoprecipitated with 2B12 Mab and quantitated 
by immunogold blots. The activity of equivalent 
immunoreactive amounts of either mutant or non- 
mutated recombinant NEPs was assayed by 
measuring the rate of [3H]Leu-enkephalin 
hydrolysis. 
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No hydrolysis of the substrate above the 
background level was observed for either 
Phe-583-NEP or Phe-587-NEP after a 60 min in- 
cubation (fig.2a). Based on the sensitivity of our 
enzymatic assays, the specific activities of these 
mutated enzymes were therefore estimated to be at 
least 5OCLfold lower than that of the non-mutated 
recombinant enzyme. These results show that 
substituting a Phe residue for either His-583 or 
His-587 drastically reduces NEP activity. 
To further probe the importance of these amino 
acid residues in the catalytic site of the enzyme, we 
next studied the binding of [3H]HACBO-Gly to 
both the non-mutated and the mutated enzymes 
Phe-583-NEP and Phe-587NEP. HACBO-Gly is a 
specific inhibitor of NEP [17] whose binding to the 
active site of the enzyme is strictly dependent on 
the presence of the Zn atom [20]. No binding was 
detected with cells expressing Phe-583 NEP or 
Phe-587 NEP (fig.3a). As binding was directly per- 
formed on suspensions of transfected cells these 
results could be explained by the failure of these 
mutated recombinant enzymes to reach the cell 
surface. In a control experiment, however, these 
cells were found to bind rz51-Mab to the same ex- 
tent as cells transfected with the non-mutated ex- 
pression vector (not shown), suggesting that the 
normal amounts of mutated recombinant enzyme 
were reaching the cell surface. Moreover, muta- 
tions of amino acids present in the NEP active site 
but not involved in HACBO-Gly recognition, such 
as Glu-584, did not modify the affinity of the en- 
zyme for the inhibitor [15]. 
It has been reported that an essential histidine 
residue is present at the active site of NEP [l I]. 
This was shown by DEPC treatment of the native 
enzyme which resulted in virtually complete inac- 
TLN 
NEP gg$$B”Q ‘a f:; 
Fig. 1. Homology between amino acid sequence of thermolysin 
(TLN) and NEP. Numbers refer to the last amino acid position 
in each protein segment. Asterisks indicate the position of Zn- 
coordinating and catalytic residues in thermolysin. Identical 
residues are boxed while conservative amino acid changes are 
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Fig.2. Activity of non-mutated and mutated NEP. COS-1 cells 
were transfected with either pSVENK19, pSVENK19-3, 
pSVENK19-6 or pSVENK19-7. The recombinant enzymes were 
purified from cell extracts by immunoprecipitation and assayed 
for [3H]Leu-enkephalin hydrolysis. (a) Rate of hydrolysis of 
[‘H]Leu-enkephalin. The activity of non-mutated and mutated 
NEP was determined by measuring the rate of hydrolysis of 
[“H]Leu-enkephalin (30 nM). (b) Eadie-Hofstee plots. (a) 
Non-mutated NEP; (0) Phe-637-NEP; (A) Phe-583 NEP; (A) 
Phe-587~NEP. All assays were performed in triplicates. 
tivation. In thermolysin, crystallographic data 
have shown the presence of His-231 at the active 
site [23]. According to Hangauer et al. [16], this 
histidine residue participates in the stabilization of 
both the Michaelis complex and the tetrahedral in- 
termediate. As mentioned above, His-231 of ther- 
moIysin might correspond to His-637 in NEP 
(fig.1). To directly test the importance of His-637 
in catalysis, we prepared a recombinant enzyme 
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Fig.3. Binding of [3H]HACBO-Gly to non-mutated and mutated NEP. Binding was performed on COS-1 cells transfected with either 
pSVENK19, pSVENK19-3. pSVENK19-6 or pSVENK19-7 as described in section 2. (a) Saturation curves of specific [3H]HACBO-Gly 
binding to COS-1 cells: non-specific binding was determined in the presence of 1 pM thiorphan. All assays were performed in 
triplicates. (b) Scatchard plots: Kd values were deduced from the slopes and calculated from two independent experiments: non- 
mutated NEP; 1.4 nM, Phe-637-NEP: 1.6 nM. (0) Non-mutated NEP; (0) Phe-637-NEP; (A) Phe-583-NEP; (A) Phe-587-NEP. 
where this residue had been changed for a 
phenylalanine and we analyzed this mutant enzyme 
for catalytic activity, [3H]HACBO-Gly binding 
and sensitivity to DEPC. Fig.2a shows that 
Phe-637-NEP hydrolysed the substrate at a rate 
similar to that of the non-mutated enzyme. The 
values of kcat and K, determined from Eadie- 
Hofstee plots were found to be very similar for 
both Phe-637-NEP (kcat = 500 min-r, Km = 
20 PM) and non-mutated NEP (kcat = 550 min-‘, 
Table 1 
Effects of DEPC modification of non-mutated and 
Phe-637-NEP 
Enzyme Enzyme activity 
Control 2 mM DEPC 2 mM DEPC + 
2 mM Phe-Leu 
Non-mutated NEP 100% 15% 92% 
Phe-NEP 100% 12% 95% 
Enzyme activity corresponds to the initial rate of hydrolysis of 
25 nM [‘H]Leu-enkephalin 
K,,, = 22 PM) (fig.2b). Furthermore the affinity of 
Phe-637-NEP for [3H]HACBO-Gly (& = 1.6 nM) 
was very similar to that of the non-mutated NEP 
(Kd = 1.4 nM) as shown by the Scatchard plots of 
fig.3b. Finally, both the mutated Phe-637~NEP 
and the non-mutated enzyme are inactivated to the 
same extent by DEPC treatment (table 1). In both 
cases this inactivation can largely be prevented by 
preincubating the enzyme in the presence of 2 mM 
Phe-Leu, a NEP competitive inhibitor (Ki = 
20 pM). Taken together, these results strongly sug- 
gest that His-637 does not play any significant role 
in catalysis. 
4. DISCUSSION 
The drastic reduction of the rate of substrate 
hydrolysis observed for the recombinant NEP 
mutants where His-583 or His-587 has been re- 
placed by a phenylalanine residue suggests that 
these two histidines are essential for catalysis. Con- 
sidering the similarity between this region of NEP 
and the sequence of thermolysin that contains the 
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two zinc-coordinating histidines, we propose that 
His-583 and His-587 of NEP are two of the zinc 
ligands. This conclusion is also supported by our 
observation that Phe-583~NEP and Phe-587-NEP 
are unable to bind HACBO-Gly, a non- 
hydrolysable substrate-derived inhibitor of NEP 
designed to interact with the metal atom [20]. 
Given the small amounts of recombinant en- 
zyme synthesized by COS-1 cells, it has not been 
possible to directly verify the absence of a Zn atom 
in these mutant NEP molecules by chemical or 
isotopic methods. Therefore we cannot completely 
rule out the possibility that failure of these recom- 
binant enzymes to hydrolyse the substrates at a 
significant rate and to bind HACBO-Gly is the 
result of a profound alteration of enzyme subsites. 
We however believe this to be a very unlikely 
possibility for two reasons: (i) other mutations in- 
troduced in the same area of the NEP molecule 
such as the substitution of Ile-585 for Phe had no 
effect on neither HACBO-Gly binding nor 
catalytic activity (Devault, unpublished); (ii) the 
non-conservative change of the active site Glu-584 
for Val completely abolishes the catalytic activity 
but does not grossly distort the enzyme structure as 
indicated by the normal Kd for [3H]HACBO-Gly 
1151. 
In contrast the apparent lack of change in the 
catalytic and binding properties of NEP following 
replacement of His-637 by Phe, suggests that this 
His residue is not involved in the stabilization of 
the transition state and therefore does not corre- 
spond to His-231 of thermolysin. This is reinforced 
by the sensitivity of mutated Phe-637-NEP to 
chemical modification induced by the His reagent 
DEPC. Additional experiments are therefore re- 
quired to assign all the amino acids present in the 
active site. 
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